Goldman Sachs Maintains Neutral on HUTCHMED (China), Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Paul Choi has maintained a Neutral rating on HUTCHMED (China) (NASDAQ:HCM) but increased the price target from $15 to $17.
November 10, 2023 | 4:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs has maintained a Neutral rating on HUTCHMED (China) but raised the price target from $15 to $17, indicating a positive outlook on the stock's value.
The increase in price target by a reputable analyst like Goldman Sachs suggests a positive reassessment of HUTCHMED's value, which could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100